The upregulation of IL-6, MCP-1, and CD40L in the setting of CAD has each been associated with worse clinical outcomes16–19, and as such, these important inflammatory factors represent additional targets for future anti-inflammatory CAD therapy. This evidence concerns the gene CD40LG and coronary artery disorder.